Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BDM-2 in Bottle (50 mg - 3600 mg); oral suspension
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Hivih
- Target Recruit Count
- 16
- Registration Number
- NCT03634085
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath